NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Март 18, 2024
Background
After
licensing
of
the
protein-based
vaccine
NVX-CoV2373,
three
technically
different
vaccines
against
SARS-CoV-2
became
available
for
application
to
human
population
-
and
comparison
efficacies.
Methods
We
here
recruited
42
study
participants
who
had
obtained
one
initial
dose
NVX-CoV2373
analyzed
their
immune
responses
in
contrast
37
either
vector
AZD1222
or
mRNA
BNT162b2
a
year
earlier.
32
also
donated
blood
before
first
vaccination
serve
as
vaccine-naive
control.
In
detail,
we
investigated
quantified
at
day
21
approximately
six
months
after
primary
immunization
amounts
vaccine-specific
antibodies
produced,
neutralization
capacity,
quality
terms
binding
epitopes
efficiency
inducing
various
isotypes.
Cellular
immunity
intracellular
cytokine
production
following
vitro
re-stimulation
with
was
via
ELISpot
flow
cytometry.
Results
Our
results
show
that
even
though
including
yielded
best
almost
any
aspect
antibody
levels
efficiency,
capacities
wild-type
Wuhan
strain
Omicron
BA.1
variant
early
were
comparable
among
all
groups.
As
T
cells,
observed
prevailing
CD8
response
weeks
which
turned
into
predominant
CD4
memory
has
not
yet
been
BNT162b2.
While
additional
infection
resulted
boost
humoral
response,
cell
appeared
rather
unaffected.
Conclusion
Whether
these
differences
translate
real
world
protection
from
infection,
mitigation
severe
disease
courses
prevention
long/post
COVID
will
need
be
future.
Язык: Английский
Editorial for SARS-CoV-2 and COVID-19 Topical Collection
Viruses,
Год журнала:
2024,
Номер
16(3), С. 356 - 356
Опубликована: Фев. 25, 2024
A
previously
unknown
coronavirus,
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2),
was
isolated
in
Wuhan,
China
December
2019,
from
a
patient
with
disease
linked
to
potential
contact
wild
animals
[...]
Язык: Английский
Potential of a Bead-Based Multiplex Assay for SARS-CoV-2 Antibody Detection
Biology,
Год журнала:
2024,
Номер
13(4), С. 273 - 273
Опубликована: Апрель 18, 2024
Serological
assays
for
SARS-CoV-2
play
a
pivotal
role
in
the
definition
of
whether
patients
are
infected,
understanding
viral
epidemiology,
screening
convalescent
sera
therapeutic
and
prophylactic
purposes,
obtaining
better
immune
response
towards
virus.
The
aim
this
study
was
to
investigate
performance
bead-based
multiplex
assay.
This
assay
allowed
simultaneous
testing
IgG
antibodies
against
spike,
S1,
S2,
RBD,
nucleocapsid
moieties
S1
seasonal
coronaviruses
hCoV-22E,
hCoV-HKU1,
hCoV-NL63,
hCoV-OC43,
as
well
MERS
SARS-CoV.
We
compared
with
commercial
ELISA
tests.
tested
27
PCR-positive
individuals
who
were
previously
different
assays.
Additionally,
we
investigated
reproducibility
results
by
means
multiple
same
sera.
Finally,
correlated
neutralising
In
summary,
concordance
qualitative
ranged
between
78%
96%
depending
on
specific
antigen.
Repeated
freezing-thawing
cycles
resulted
reduced
mean
fluorescence
intensity,
while
storage
period
had
no
influence
respect.
our
test
cohort,
detected
up
36%
positive
development
antibodies,
which
is
ELISA.
Язык: Английский